Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib + Palbociclib + Letrozole/Fulvestrant in MBC
NCT02684032Phase 1Completed
- Sponsor
- Celcuity Inc.
- Start
- Jun 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gedatolisib in breast cancer (6 arms), sponsored by Celcuity Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response Rate at 16 weeks. Started Jun 2016; status: completed.
02
Drugs
gedatolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02684032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684032.